The mean age was 36 years for Luminal B, 34 years for triple-negative breast cancer (TNBC), and 37 years for HER2 neu (Table 2). On ultrasound, HER2-neu (n=7, 43.8%) and Luminal A and B combined (n=13, 54.5%) had indistinct margins predominantly, and TNBC had microlobulated margins (n=10, 55.6%) (Figure 3). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.